Serious adverse events occurred in eight ( @ % ) patients in the triple-treatment group and five ( @ % ) in the dual-treatment group ( p = @ ) , and study drug discontinuations due to adverse events occurred in four ( @ % ) in the triple-treatment group and one ( @ % ) in the dual-treatment group ( p = @ ) .